drugset / Trial / NCT01580306
Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control group with normal renal function after single dose of BI 201335.
Timeline
- Start
- 2012-04
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faldaprevir | Small molecule | — | Oral |